Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022
CINCINNATI, Jan. 10, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022. Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in […]
Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay
CINCINNATI, Jan. 5, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food and Drug Administration (FDA) clearance. The Curian Campy assay is a rapid, qualitative fluorescent immunoassay for the detection of a Campylobacter-specific antigen including C. jejuni, C. coli, C. […]
Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference
CINCINNATI, Jan. 4, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H. C. Wainwright Bioconnect Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on January 10, 2022. Webcast links to Meridian’s presentation will be available […]